The Post-COVID-19 Functional Status scale: a tool to measure functional status over time after COVID-19

Frederikus A Klok, Gudula J A M Boon, Stefano Barco, Matthias Endres, J J Miranda Geelhoed, Samuel Knauss, Spencer A Rezek, Martijn A Spruit, Jörg Vehreschild, Bob Siegerink, Frederikus A Klok, Gudula J A M Boon, Stefano Barco, Matthias Endres, J J Miranda Geelhoed, Samuel Knauss, Spencer A Rezek, Martijn A Spruit, Jörg Vehreschild, Bob Siegerink

Abstract

An ordinal tool is proposed to measure the full spectrum of functional outcomes following COVID-19. This “Post-COVID-19 Functional Status (PCFS) scale” can be used for tracking functional status over time as well as for research purposes. https://bit.ly/3cofGaa

Conflict of interest statement

Conflict of interest: F.A. Klok reports grants from Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Daiichi Sankyo, MSD, Actelion, the Netherlands Thrombosis Foundation and the Dutch Heart Foundation, outside the submitted work. Conflict of interest: G.J.A.M. Boon has nothing to disclose. Conflict of interest: S. Barco has nothing to disclose. Conflict of interest: M. Endres reports grants from DFG under Germany's Excellence Strategy (EXC-2049; 390688087) and Bayer, and personal fees from Bayer, Boehringer Ingelheim, BMS, Daiichi Sankyo, Amgen, GSK, Sanofi, Covidien, Novartis and Pfizer, outside the submitted work. Conflict of interest: J.J.M. Geelhoed has nothing to disclose. Conflict of interest: S. Knauss has nothing to disclose. Conflict of interest: S.A. Rezek has nothing to disclose. Conflict of interest: M.A. Spruit reports grants from the Netherlands Lung Foundation and Stichting Astma Bestrijding, and grants and personal fees from AstraZeneca and Boehringer Ingelheim, outside the submitted work. Conflict of interest: J. Vehreschild has nothing to disclose. Conflict of interest: B. Siegerink has nothing to disclose.

Figures

FIGURE 1
FIGURE 1
Patient self-report methods for the Post-COVID-19 Functional Status (PCFS) scale. a) Flowchart. b) Patient questionnaire. Instructions for use: 1) to assess recovery after the SARS-CoV-2 infection, this PCFS scale covers the entire range of functional limitations, including changes in lifestyle, sports and social activities; 2) assignment of a PCFS scale grade concerns the average situation of the past week (exception: when assessed at discharge, it concerns the situation of the day of discharge); 3) symptoms include (but are not limited to) dyspnoea, pain, fatigue, muscle weakness, memory loss, depression and anxiety; 4) in case two grades seem to be appropriate, always choose the highest grade with the most limitations; 5) measuring functional status before the infection is optional; 6) alternatively to this flowchart and patient questionnaire, an extensive structured interview is available. The full manual for patients and physicians or study personnel is available from https://osf.io/qgpdv/ (free of charge).

References

    1. Johns Hopkins University Coronavirus Resource Center. Date last accessed: April 2020.
    1. Simpson R, Robinson L. Rehabilitation after critical illness in people with COVID-19 infection. Am J Phys Med Rehabil 2020; 99: 470–474. doi:10.1097/PHM.0000000000001443
    1. Ngai JC, Ko FW, Ng SS, et al. . The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology 2010; 15: 543–550. doi:10.1111/j.1440-1843.2010.01720.x
    1. Tansey CM, Louie M, Loeb M, et al. . One-year outcomes and health care utilization in survivors of severe acute respiratory syndrome. Arch Intern Med 2007; 167: 1312–1320. doi:10.1001/archinte.167.12.1312
    1. Neufeld KJ, Leoutsakos J-MS, Yan H, et al. . Fatigue symptoms during the first year following ARDS. Chest 2020; in press [10.1016/j.chest.2020.03.059].
    1. Siegerink B, Rohmann JL. Impact of your results: beyond the relative risk. Res Pract Thromb Haemost 2018; 2: 653–657. doi:10.1002/rth2.12148
    1. Boon GJAM, Barco S, Bertoletti L, et al. . Measuring functional limitations after venous thromboembolism: optimization of the post-VTE functional status (PVFS) scale. Thromb Res 2020; 190: 45–51. doi:10.1016/j.thromres.2020.03.020
    1. Klok FA, Barco S, Siegerink B. Measuring functional limitations after venous thromboembolism: a call to action. Thromb Res 2019; 178: 59–62. doi:10.1016/j.thromres.2019.04.003
    1. World Health Organization WHO R&D Blueprint. Novel Coronavirus: COVID-19 Therapeutic Trial Synopsis. Draft February 18, 2020.
    1. Lodigiani C, Iapichino G, Carenzo L, et al. . Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res 2020; 191: 9–14. doi:10.1016/j.thromres.2020.04.024
    1. Klok FA, Kruip MJHA, van der Meer NJM, et al. . Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145–147. doi:10.1016/j.thromres.2020.04.013

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe